Advanced Kidney Cancer VL

First-line Therapy Options for Metastatic Renal Cell Carcinoma - Tian Zhang

Details
Tian Zhang, MD and Monty Pal, MD review first-line therapy options for metastatic renal cell carcinoma (mRCC), including immunotherapy- based ipilimumab, nivolumab, pembrolizumab, axitinib, as well as avelumab/axitinib combinations and cabozantinib monotherapy. Tian continues focusing on achieving a complete response rate, and treating intermediate, poor-risk disease where she describes an excitin...

The Dynamic Landscape of mRCC and the PDIGREE Trial - Tian Zhang

Details
Tian Zhang, MD shares her thoughts with Alicia Morgans, MD on the three new approvals for the first line treatment of metastatic renal cell carcinoma, including cabozantinib with targeted agents, IO combinations with ipilimumab and nivolumab and now the recent approval of pembrolizumab plus axitinib. Dr. Zhang reviews the long-term follow-up from the CHECKMATE-214 study along with the CABOSUN data...

Newly Approved Treatment Options for the Management of Metastatic Kidney Cancer- Lauren Harshman and Toni Choueiri

Details
Lauren Harshman, MD, Alicia Morgans, MD and Toni Choueiri, MD discuss combination therapy for the management of metastatic kidney cancer with the recent approval of pembrolizumab plus axitinib. The combination was approved for all patients regardless of risk category. This adds to the treatment armamentarium for metastatic kidney cancer with the already approved nivolumab plus ipilimumab regimen....

Targeted Therapies with Immunotherapies In Kidney Cancer - Thomas Powles

Details
Thomas Powles discusses the results of the phase III KEYNOTE-426 trial presented at the 2019 Genitourinary Cancers Symposium with Charles Ryan. The checkpoint inhibitor pembrolizumab plus the vascular endothelial growth factor (VEGF) tyrosine kinase inhibitor axitinib significantly improved overall survival, progression-free survival, and objective response rates vs sunitinib as first-line therapy...

Rapidly Evolving Landscape in Metastatic Renal Cell Carcinoma- Rana McKay

Details
Rana McKay, MD reviews the evolving landscape for the frontline treatment of metastatic RCC. Historically, patients were treated with first-line TKIs although the paradigm has been shifting over the past two years including, VEGF targeted therapy with immunotherapy and IO-IO combinations. Dr. McKay reviews the data from KEYNOTE 426 with pembrolizumab plus axitinib which demonstrated a survival ben...

Frontline Data from Keynote 426 - Sandy Srinivas

Details
Sandy Srinivas, MD discusses the frontline data from the KEYNOTE 426 trial comparing pembrolizumab plus axitinib to sunitinib monotherapy in clear cell kidney cancer. 800 patients were randomized and the combination demonstrated benefit across all three outcomes measured including response rates, PFS and overall survival. Dr. Srinivas believes the tolerability for pembrolizumab plus axitinib is mo...

Paradigm Changing Data for Kidney Cancer - Primo Lara

Details
Primo Lara, MD, and Monty Pal, MD discuss this exciting time in the evolving paradigm for the treatment of kidney cancer. They focus their discussion on the groundbreaking data presented at ASCO GU on the KEYNOTE 426 trial which demonstrated that the combination of pembrolizumab plus axitinib was superior to the VEGF RTKI, sunitinib. Overall survival with the combination demonstrated a 46% reducti...

Patient Advocacy and Resources in Kidney Cancer - Dena Battle

Details
Dena Battle, President KCCure joins Jaime Landman and Monty Pal for a discussion on development and establishing resources to assist in the fight against kidney cancer. KCCure, is a research organization that funds high-impact, high-risk kidney cancer research through a peer-review processthrough an expert team of kidney cancer specialists, patients, caregivers, and kidney cancer advocates. The gr...

Monitoring Treatment Toxicities in Patients with Renal Cell Carcinoma: discussion with Dan George and Tian Zhang

Details
Dan George and Tian Zhang share their views on monitoring treatment toxicities that patients with renal cell carcinoma may experience. Emphasis is placed on counseling patients on expectations and managing baseline comorbities. Maintaining prescribed treatment schedule while focused on quality of life remains the challenging goal for an effective treatment outcome. Biographies: Tian Zhang, MD, Ass...

ASSET, A Pilot Study Using Exercise Physiology in Advanced Renal Cell Carcinoma - Mike Harrison

Details
(Length of Discussion: 12 min) Michael Harrison discusses the ASSET trial with Alicia Morgans. ASSET is a pilot study looking at the drug sunitinib, and its impact on cardiopulmonary function in patients with metastatic kidney cancer. Harrison reviews in detail, the rationale for the study and why the phenomenology of fatigue using exercise physiology may be useful information for clinicians in th...
E-Newsletters

Newsletter subscription

Free Daily and Weekly newsletters offered by content of interest

The fields of GU Oncology and Urology are rapidly advancing. Sign up today for articles, videos, conference highlights and abstracts from peer-review publications by disease and condition delivered to your inbox and read on the go.

Subscribe